16 Minutes on the News #38: Teladoc & Livongo, Is Virtual Care Fully Here?

    In this episode of 16 Minutes — our show where we cover recent headlines; tease apart what’s hype/ what’s real; and help orient where we are, trends-wise, on the long arc of innovation — we cover the merger of Teladoc and Livongo, which was announced just a few days ago. The $18.5B deal is a big deal not just because of the dollars and validation in public markets, but because it’s aimed at creating “the first true health tech giant“, and an end-to-end digital health platform at scale. However, the scale and opportunity in healthcare is so massive — this is akin to a reasonably sized hospital system — that this may be a drop in the bucket of what’s out there.

    And beyond the buzz, where are we, really, when it comes to the broader category here of virtual care? What’s our taxonomy of key trends and shifts such as telehealth/ telemedicine, remote patient monitoring, and virtual care? Given that this deal and virtual care itself was accelerated during the pandemic — is “the pandemic effect” a harbinger or will we see the rubber band snap back once things go “back to normal” (is THIS the new normal)? Where do specific policies and regulations come in, such as for reimbursement, physician licensing, and more?

    General partners Julie Yoo and Vijay Pande break it all down in conversation with host Sonal Chokshi. We also discuss what it takes, practically, to not just merge the two entities but meet in the middle of the spectrum; what the implications are for incumbents (including payers and providers) and startups; and where go-to-market and partnerships come in. Distribution, as always, is everything.

    The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein.

    This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/.

    Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

    Biology is eating the world

    Sign up for our bio newsletter to get the a16z take on the future of biology and engineering.